miR-199a-3p can affect the sensitivity of hepatocellular carcinoma cells to doxorubicin by direct role in the target of rapamycin and c-Met, and maintain the low level expression of miR-199a-3p could improve the therapeutic effect of doxorubicin. This evidence concerns the gene MET and hepatocellular carcinoma.